Correction to: Endothelial actions of atrial natriuretic peptide prevent pulmonary hypertension in mice (Basic Research in Cardiology, (2016), 111, 2, (22), 10.1007/s00395-016-0541-x);Endothelial actions of atrial natriuretic peptide prevent pulmonary hypertension in mice

Basic Research in Cardiology

Volumn 111, Issue 2, 2016, Pages 1-16

  Werner, Franziska ^a   Kojonazarov, Baktybek ^b,c   Gaßner, Birgit ^a   Abeßer, Marco ^a   Schuh, Kai ^a   Völker, Katharina ^a   Baba, Hideo A ^d   Dahal, Bhola K ^b,c   Schermuly, Ralph T ^b,c   Kuhn, Michaela ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^c German Center for Lung Research   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Atrial natriuretic peptide; Cyclic GMP; Endothelium; Guanylyl cyclase A; Pulmonary hypertension

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE; GUANYLATE CYCLASE ACTIVATOR; LOSARTAN; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR RECEPTOR; ENDOTHELIN 1; NATRIURETIC PEPTIDE RECEPTOR A;

ARTERIAL PRESSURE; ARTERY; ARTICLE; CELL CULTURE; DISEASE COURSE; ENDOTHELIUM CELL; EXPERIMENTAL PULMONARY HYPERTENSION; HEART RIGHT VENTRICLE FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPOXIA; INFLAMMATION; INFLAMMATORY CELL; LUNG ALVEOLUS CELL; LUNG ENDOTHELIUM; MORPHOMETRICS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SMOOTH MUSCLE MEDIATED VASODILATATION; THROMBOSIS; VASODILATATION; WESTERN BLOTTING; ANIMAL; ENZYMOLOGY; GENETICS; HYPERTENSION, PULMONARY; KNOCKOUT MOUSE; LUNG; METABOLISM;

ANGIOTENSIN II; ANIMALS; ATRIAL NATRIURETIC FACTOR; ENDOTHELIAL CELLS; ENDOTHELIN-1; HYPERTENSION, PULMONARY; HYPOXIA; LUNG; MICE; MICE, KNOCKOUT; PEPTIDYL-DIPEPTIDASE A; RECEPTORS, ATRIAL NATRIURETIC FACTOR;

EID: 84959088737     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-022-00916-9     Document Type: Erratum

References (58)

1. Aguirre JI, Morrell NW, Long L, Clift P, Upton PD, Polak JM, Wilkins MR (2000) Vascular remodeling and ET-1 expression in rat strains with different responses to chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 278:L981–L987
2. Agulló L, Garcia-Dorado D, Escalona N, Inserte J, Ruiz-Meana M, Barrabés JA, Mirabet M, Pina P, Soler-Soler J (2002) Hypoxia and acidosis impair cGMP synthesis in microvascular coronary endothelial cells. Am J Physiol 283:H917–H925. doi:10.1152/ajpheart.01067.2001
3. Archer SL, Weir EK, Wilkins MR (2010) Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 121:2045–2066. doi:10.1161/CIRCULATIONAHA.108.847707
4. Arndt PG, Young SK, Poch KR, Nick JA, Falk S, Schrier RW, Worthen GS (2006) Systemic inhibition of the angiotensin-converting enzyme limits lipopolysaccharide-induced lung neutrophil recruitment through both bradykinin and angiotensin II-regulated pathways. J Immunol 177:7233–7241. doi:10.4049/jimmunol.177.10.7233
5. Baliga RS, Zhao L, Madhani M, Lopez-Torondel B, Visintin C, Selwood D, Wilkins MR, MacAllister RJ, Hobbs AJ (2008) Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. Am J Respir Crit Care Med 178:861–869. doi:10.1164/rccm.200801-121OC
6. Baxter GF (2004) The natriuretic peptides. Basic Res Cardiol 99:71–75. doi:10.1007/s00395-004-0457-8
7. Bubb KJ, Trinder SL, Baliga RS, Patel J, Clapp LH, MacAllister RJ, Hobbs AJ (2014) Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension. Circulation 130:496–507. doi:10.1161/CIRCULATIONAHA.114.009751
8. Cargill RI, Lipworth BJ (1995) Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans. Br J Clin Pharmacol 40:585–590. doi:10.1111/j.1365-2125.1995.tb05803.x
9. Casserly B, Klinger JR (2009) Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. Drug Des Dev Ther 3:269–287. doi:10.2147/DDDT.S4805
10. Casserly B, Pietras L, Schuyler J, Wang R, Hill NS, Klinger JR (2010) Cardiac atria are the primary source of ANP release in hypoxia-adapted rats. Life Sci 87:382–389. doi:10.1016/j.lfs.2010.07.013
11. Chun YS, Hyun JY, Kwak YG, Kim IS, Kim CH, Choi E, Kim MS, Park JW (2003) Hypoxic activation of the atrial natriuretic peptide gene promoter through direct and indirect actions of hypoxia-inducible factor-1. Biochem J 370:149–157. doi:10.1042/BJ20021087
12. Clozel JP, Saunier C, Hartemann D, Fischli W (1991) Effects of cilazapril, a novel angiotensin converting enzyme inhibitor, on the structure of pulmonary arteries of rats exposed to chronic hypoxia. J Cardiovasc Pharmacol 17:36–40
13. Crapo JD, Barry BE, Gehr P, Bachofen M, Weibel ER (1982) Cell number and cell characteristics of the normal human lung. Am Rev Respir Dis 126:332–337
14. de Man FS, Tu L, Handoko ML, Rain S, Ruiter G, François C, Schalij I, Dorfmüller P, Simonneau G, Fadel E, Perros F, Boonstra A, Postmus PE, van der Velden J, Vonk-Noordegraaf A, Humbert M, Eddahibi S, Guignabert C (2012) Dysregulated renin–angiotensin–aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med 186:780–789. doi:10.1164/rccm.201203-0411OC
15. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, Stasch JP, Gnoth MJ, Seeger W, Grimminger F, Schermuly RT (2006) Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 113:286–295. doi:10.1161/CIRCULATIONAHA.105.581405
16. Ferrario CM, Strawn WB (2006) Role of the renin–angiotensin–aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 98:121–128. doi:10.1016/j.amjcard.2006.01.059
17. Fraccarollo D, Galuppo P, Motschenbacher S, Ruetten H, Schäfer A, Bauersachs J (2014) Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition. Basic Res Cardiol 109:421. doi:10.1007/s00395-014-0421-1
18. Frantz S, Klaiber M, Baba HA, Oberwinkler H, Völker K, Gaßner B, Bayer B, Abeßer M, Schuh K, Feil R, Hofmann F, Kuhn M (2013) Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase I. Eur Heart J 34:1233–1244. doi:10.1093/eurheartj/ehr445
19. Fujita S, Shimojo N, Terasaki F, Otsuka K, Hosotani N, Kohda Y, Tanaka T, Nishioka T, Yoshida T, Hiroe M, Kitaura Y, Ishizaka N, Imanaka-Yoshida K (2013) Atrial natriuretic peptide exerts protective action against angiotensin II-induced cardiac remodeling by attenuating inflammation via endothelin-1/endothelin receptor A cascade. Heart Vessels 28:646–657. doi:10.1007/s00380-012-0311-0
20. Guignabert C, Alvira CM, Alastalo TP, Sawada H, Hansmann G, Zhao M, Wang L, El-Bizri N, Rabinovitch M (2009) Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization. Am J Physiol 297:L1082–L1090. doi:10.1152/ajplung.00199.2009
21. Guignabert C, Tu L, Girerd B, Ricard N, Huertas A, Montani D, Humbert M (2015) New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication. Chest 147:529–537. doi:10.1378/chest.14-0862
22. Höhne C, Drzimalla M, Krebs MO, Boemke W, Kaczmarczyk G (2003) Atrial natriuretic peptide ameliorates hypoxic pulmonary vasoconstriction without influencing systemic circulation. J Physiol Pharmacol 54:497–510
23. Hong KH, Lee YJ, Lee E, Park SO, Han C, Beppu H, Li E, Raizada MK, Bloch KD, Oh SP (2008) Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation 118:722–730. doi:10.1161/CIRCULATIONAHA.107.736801
24. Hutchinson HG, Trindade PT, Cunanan DB, Wu CF, Pratt RE (1997) Mechanisms of natriuretic peptide-induced growth inhibition of vascular smooth muscle cells. Cardiovasc Res 35:158–167. doi:10.1016/S0008-6363(97)00086-2
25. Irwin DC, Tissot van Patot MC, Tucker A, Bowen R (2005) Direct ANP inhibition of hypoxia-induced inflammatory pathways in pulmonary microvascular and macrovascular endothelial monolayers. Am J Physiol 288:L849–L859. doi:10.1152/ajplung.00294.2004
26. Jin H, Yang RH, Chen YF, Jackson RM (1991) Atrial natriuretic peptide in acute hypoxia-induced pulmonary hypertension in rats. J Appl Physiol 71:807–814
27. Kilić A, Bubikat A, Gassner B, Baba HA, Kuhn M (2007) Local actions of atrial natriuretic peptide counteract angiotensin II stimulated cardiac remodeling. Endocrinology 148:4162–4169. doi:10.1210/en.2007-0182
28. Klinger JR, Warburton RR, Pietras LA, Smithies O, Swift R, Hill NS (1999) Genetic disruption of atrial natriuretic peptide causes pulmonary hypertension in normoxic and hypoxic mice. Am J Physiol 276:L868–L874
29. Klinger JR, Warburton RR, Pietras L, Oliver P, Fox J, Smithies O, Hill NS (2002) Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy. Am J Physiol 282:H58–H65
30. Kuhn M (2012) Endothelial actions of atrial and B-type natriuretic peptides. Br J Pharmacol 166:522–531. doi:10.1111/j.1476-5381.2012.01827.x
31. Kuhn M, Völker K, Schwarz K, Carbajo-Lozoya J, Flögel U, Jacoby C, Stypmann J, van Eickels M, Gambaryan S, Hartmann M, Werner M, Wieland T, Schrader J, Baba HA (2009) The natriuretic peptide/guanylyl cyclase-A system functions as a stress-responsive regulator of angiogenesis in mice. J Clin Invest 119:2019–2030. doi:10.1172/JCI37430
32. Liu LS, Cheng HY, Chin WJ, Jin HK, Oparil S (1989) Atrial natriuretic peptide lowers pulmonary arterial pressure in patients with high altitude disease. Am J Med Sci 298:397–401
33. Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, Friesen J, Garbers DL, Beuve A (1995) Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 378:65–68. doi:10.1038/378065a0
34. Madjdpour C, Jewell UR, Kneller S, Ziegler U, Schwendener R, Booy C, Kläusli L, Pasch T, Schimmer RC, Beck-Schimmer B (2003) Decreased alveolar oxygen induces lung inflammation. Am J Physiol Lung Cell Mol Physiol 284:L360–L367. doi:10.1152/ajplung.00158.2002
35. Maron BA, Leopold JA (2014) The role of the renin–angiotensin–aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series). Pulm Circ 4:200–210. doi:10.1086/675984
36. Minamino T, Christou H, Hsieh CM, Liu Y, Dhawan V, Abraham NG, Perrella MA, Mitsialis SA, Kourembanas S (2001) Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci USA 98:8798–8803. doi:10.1073/pnas.161272598
37. Morrell NW, Atochina EN, Morris KG, Danilov SM, Stenmark KR (1995) Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. J Clin Invest 96:1823–1833. doi:10.1172/JCI118228
38. Morrell NW, Morris KG, Stenmark KR (1995) Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am J Physiol 269:H1186–H1194
39. el Mtairag M, Houard X, Rais S, Pasquier C, Oudghiri M, Jacob MP, Meilhac O, Michel JB (2002) Pharmacological potentiation of natriuretic peptide limits polymorphonuclear neutrophil–vascular cell interactions. Arterioscler Thromb Vasc Biol 22:1824–1831. doi:10.1161/01.ATV.0000037102.31086.F4
40. Nakamoto T, Harasawa H, Akimoto K, Hirata H, Kaneko H, Kaneko N, Sorimachi K (2005) Effects of olmesartan medoxomil as an angiotensin II-receptor blocker in chronic hypoxic rats. Eur J Pharmacol 528:43–51. doi:10.1016/j.ejphar.2005.10.063
41. National Institutes of Health. Guide for the care and use of laboratory animals. NIH publication, 85-231996
42. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, Guiducci C, Kathiresan S, Benjamin EJ, Struck J, Morgenthaler NG, Bergmann A, Blankenberg S, Kee F, Nilsson P, Yin X, Peltonen L, Vartiainen E, Salomaa V, Hirschhorn JN, Melander O, Wang TJ (2009) Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 41:348–353. doi:10.1038/ng.328
43. Orte C, Polak JM, Haworth SG, Yacoub MH, Morrell NW (2000) Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension. J Pathol 192:379–384. doi:10.1002/1096-9896
44. Pfeifer M, Wolf K, Blumberg FC, Elsner D, Muders F, Holmer SR, Riegger GA, Kurtz A (1997) ANP gene expression in rat hearts during hypoxia. Pflugers Arch 434:63–69
45. Rabinovitch M (2008) Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 118:2372–2379. doi:10.1172/JCI33452
46. Sabrane K, Kruse MN, Fabritz L, Zetsche B, Mitko D, Skryabin BV, Zwiener M, Baba HA, Yanagisawa M, Kuhn M (2005) Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest 115:1666–1674. doi:10.1172/JCI23360
47. Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Voswinckel R, Fink L, Scheed A, Ritter C, Dahal BK, Vater A, Klussmann S, Ghofrani HA, Weissmann N, Klepetko W, Banat GA, Seeger W, Grimminger F, Schermuly RT (2012) Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 186:897–908. doi:10.1164/rccm.201202-0335OC
48. Schröter J, Zahedi RP, Hartmann M, Gassner B, Gazinski A, Waschke J, Sickmann A, Kuhn M (2010) Homologous desensitization of guanylyl cyclase A, the receptor for atrial natriuretic peptide, is associated with a complex phosphorylation pattern. FEBS J 277:2440–2453. doi:10.1111/j.1742-4658.2010.07658.x
49. 1 receptor antagonist, on hypoxia-induced activation of ERK1/2 and pro-inflammatory signals in the mouse lung. Naunyn Schmiedebergs Arch Pharmacol 374:235–248. doi:10.1007/s00210-006-0110-1
50. Taraseviciene-Stewart L, Scerbavicius R, Stewart JM, Gera L, Demura Y, Cool C, Kasper M, Voelkel NF (2005) Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy. Peptides 26:1292–1300. doi:10.1016/j.peptides.2005.03.050
51. Tian Y, Mambetsariev I, Sarich N, Meng F, Birukova AA (2015) Role of microtubules in attenuation of PepG-induced vascular endothelial dysfunction by atrial natriuretic peptide. Biochim Biophys Acta 1852:104–119. doi:10.1016/j.bbadis.2014.10.012
52. Tsuneyoshi H, Nishina T, Nomoto T, Kanemitsu H, Kawakami R, Unimonh O, Nishimura K, Komeda M (2004) Atrial natriuretic peptide helps prevent late remodeling after left ventricular aneurysm repair. Circulation 110:174–179. doi:10.1161/01.CIR.0000138348.77856.ef
53. van Suylen RJ, Aartsen WM, Smits JF, Daemen MJ (2013) Dissociation of pulmonary vascular remodeling and right ventricular pressure in tissue angiotensin-converting enzyme-deficient mice under conditions of chronic alveolar hypoxia. Am J Respir Crit Care Med 163:1241–1245. doi:10.1164/ajrccm.163.5.2003144
54. Wong WT, Tian XY, Xu A, Ng CF, Lee HK, Chen ZY, Au CL, Yao X, Huang Y (2010) Angiotensin II type 1 receptor-dependent oxidative stress mediates endothelial dysfunction in type 2 diabetic mice. Antioxid Redox Signal 13:757–768. doi:10.1089/ars.2009.2831
55. Yoshida H, Nakamura M, Makita S, Hiramori K (1994) Inhibitory effect of atrial natriuretic peptide on accelerated endothelin secretion from cultured human endothelial cells. J Atheroscler Thromb 1:76–79
56. Zhao L, Winter RJ, Krausz T, Hughes JM (1991) Effects of continuous infusion of atrial natriuretic peptide on the pulmonary hypertension induced by chronic hypoxia in rats. Clin Sci (Lond) 81:379–385. doi:10.1042/cs0810379
57. Zhao L, al-Tubuly R, Sebkhi A, Owji AA, Nunez DJ, Wilkins MR (1996) Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung. Br J Pharmacol 119:1217–1222. doi:10.1111/j.1476-5381.1996.tb16025.x
58. Zhao L, Long L, Morrell NW, Wilkins MR (1999) NPR-A-deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension. Circulation 99:605–607. doi:10.1161/01.CIR.99.5.605